Fibromyalgia

TEL AVIV, Israel, April 4, 2024 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2023, with the U.S. Securities and Exchange Commission (the "SEC"). The report is available on the SEC's website, at and Galmed's Investor Relations website, at . Shareholders can obtain copies of Galmed's Annual Report on Form 20-F, free of charge, by making a request within a reasonable period of time to Galmed's Investor Relations Department at [email protected]. Galmed Pharmaceuticals Ltd. We are a clinical stage biopharmaceutical company focused on the development of Aramchol for liver and fibro-inflammatory diseases. We have focused almost exclusively on developing Aramchol for the treatment of NASH and are currently developing Aramchol for PSC and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of liver disease. We are also collaborating with the Hebrew University in the development of Amilo-5MER, a 5 amino acid synthetic peptide. Forward-Looking Statements: Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to our objectives plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that we intend, expect, project, believesor anticipate will or may occur in the future. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, our ability to pursue, evaluate and complete any strategic alternative that yields value for our shareholders; the timing and cost of our planned Primary Sclerosing Cholangitis, or PSC, clinical trial and our pivotal Phase 3 ARMOR trial, or the ARMOR Study, if re-initiated, for our product candidates, Aramchol and Amilo-5MER, or for any other pre-clinical or clinical trials; completion and receiving favorable results of our planned PSC clinical trial and the ARMOR Study (if re-initiated) for Aramchol or any other pre-clinical or clinical trial; regulatory action with respect to Aramchol or any other product candidate by the U.S. Food and Drug Administration, or FDA, the European Medicines Authority, or EMA, or the Medicines and Healthcare Products Regulatory Agency, or the MHRA, including but not limited to acceptance of an application for marketing authorization, review and approval of such application, and, if approved, the scope of the approved indication and labeling; the commercial launch and future sales of Aramchol and any future product candidates; our ability to comply with all applicable post-market regulatory requirements for Aramchol, Amilo-5MER or any other product candidate in the countries in which we seek to market the product; our ability to achieve favorable pricing for Aramchol, Amilo-5MER or any other product candidate; our expectations regarding the commercial market for PSC, non-alcoholic steato-hepatitis, or NASH (also known as MASH), in patients or any other targeted indication; third-party payor reimbursement for Aramchol, Amilo-5MER or any other product candidate; our estimates regarding anticipated capital requirements and our needs for additional financing; market adoption of Aramchol or any other product candidate by physicians and patients; the timing, cost or other aspects of the commercial launch of Aramchol or any other product candidate; our ability to obtain and maintain adequate protection of our intellectual property; the possibility that we may face third-party claims of intellectual property infringement; our ability to manufacture our product candidates in commercial quantities, at an adequate quality or at an acceptable cost; our ability to establish adequate sales, marketing and distribution channels; intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do; the development and approval of the use of Aramchol or any other product candidate for additional indications or in combination therapy; our expectations regarding licensing, acquisitions and strategic operations; current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk; our ability to maintain the listing of our ordinary shares on The Nasdaq Capital Market; security, political and economic instability in the Middle East that could harm our business, including due to the recent attacks by Hamas and other terrorist organizations from the Gaza Strip and elsewhere in the region and Israel's war against them and military hostilities with Hezbollah on the northern border of Israel. We believe these forward-looking statements are reasonable; however, these statements are only current predictions and are subject to known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements. We discuss many of these risks in our Annual Report on Form 20-F for the year ended December 31, 2023 filed with the SEC on April 4, 2024 in greater detail under the heading "Risk Factors." Given these uncertainties, you should not rely upon forward-looking statements as predictions of future events. All forward-looking statements attributable to us or persons acting on our behalf speak only as of the date hereof and are expressly qualified in their entirety by the cautionary statements included in this report. We undertake no obligations to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events. In evaluating forward-looking statements, you should consider these risks and uncertainties. Logo - SOURCE Galmed Pharmaceuticals Ltd.

electroCore Granted Two New U.S. PatentsROCKAWAY, N.J., April 02, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue notifications from the United States Patent and Trademark Office (USPTO). The two patents were issued on April 2, 2024, and relate to electroCore’s non-invasive vagus nerve stimulation (nVNS) technology: US Patent No. 11,944,815 entitled “Non-Invasive Nerve Stimulation with Mobile Device” generally relates to a system for transcutaneously stimulating a nerve in a patient that includes a downloadable software application configured to wirelessly transmit a therapy regimen to a stimulator. The therapy regimen comprises generating an electrical signal for approximately 5 minutes to 30 minutes.US Patent No. 11,944,807 entitled “Vagal Nerve Stimulation for Treating Central Nervous System Disorders” generally relates to methods for treating central nervous disorders, such as PTSD, fibromyalgia, anxiety and TBI by applying electrical impulses to the vagus nerve according to a stimulation protocol that includes at least two doses each day. The electrical impulses are bursts of 2 to 20 sinusoidal pulses. About electroCore, Inc.electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets. For more information, visit www.electrocore.com. Forward-Looking StatementsThis press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore's business prospects and clinical and product development plans; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments; the issuance of U.S. and international patents providing expanded IP coverage; the possibility of future business models, the potential of nVNS generally and gammaCore in particular and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "expects," "believes," "intends," other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to obtain additional financing necessary to continue electroCore's business, sales and marketing and product development plans, the uncertainties inherent in the development of new products or technologies, the ability to successfully commercialize gammaCore™, competition in the industry in which electroCore operates and general market conditions. All forward-looking statements are made as of the date of this press release, and electroCore undertakes no obligation to update forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should refer to all information set forth in this document and should also refer to the disclosure of risk factors set forth in the reports and other documents electroCore files with the SEC, available at www.sec.gov. Contact:ECOR Investor Relations(973) 302-9253investors@electrocore.com

“Breaking New Ground: Expert Perspectives on Primary Sclerosing Cholangitis” Will Feature Clinical, Academic and Patient Advocacy Leaders Discussing PSC Disease Management and Evolving Views on Clinical Development TEL AVIV, Israel, April 02, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics to treat rare fibro-inflammatory diseases with high unmet need, today announced it will host a live key opinion leader (KOL) virtual event on primary sclerosing cholangitis (PSC) on Wednesday, April 10, 2024 at 10:00 AM ET. To register, click here. The event, “Breaking New Ground: Expert Perspectives on Primary Sclerosing Cholangitis,” will feature Christopher Bowlus, MD (UC Davis Health), Ricky Safer (PSC Partners Seeking a Cure), and Massimo Pinzani, MD, PhD, (UCL Institute for Liver and Digestive Health, UPMC ISMETT), who will provide clinical and patient perspectives on PSC, a devastating rare liver disease with no FDA-approved therapies. They will discuss the urgent need for new PSC treatments and emerging developments that could facilitate new drug approvals. Chemomab’s co-founder, CEO & CSO Adi Mor, PhD and CMO Matt Frankel, MD, will provide an overview of the CM-101 Phase 2 PSC clinical trial that will report topline results midyear 2024. CM-101 is a dual mechanism first-in-class monoclonal antibody that neutralizes CCL24, a soluble protein that is a key driver of inflammatory and fibrotic pathways central to PSC and other fibro-inflammatory diseases. A Q&A session will follow the presentations. About Christopher Bowlus, MD Chris Bowlus, MD is the Lena Valente Professor and Chief of the Division of Gastroenterology and Hepatology at the University of California Davis School of Medicine. Dr. Bowlus has an active research program bridging the basic and clinical aspects of PSC and primary biliary cholangitis (PBC), with the goal of bringing more effective treatments to patients. He is a founding member of the International PSC Study Group and leads the U.S,-based Consortium for Autoimmune Liver Disease. Dr. Bowlus is also active in supporting patient advocacy, serving as Co-Chair of the Scientific and Medical Advisory Committee of PSC Partners Seeking a Cure. He received his BA degree from the University of California San Diego and his MD degree from the St. Louis University School of Medicine. Dr. Bowlus completed a Fellowship in Gastroenterology at the Yale University School of Medicine. About Ricky Safer Ricky Safer is a patient living with PSC and Founder and CEO of PSC Partners Seeking a Cure, a non-profit organization whose mission is to drive PSC research to identify treatments and a cure and provide education and support for those impacted by PSC. PSC Partners collaborates with researchers, clinicians, industry and regulators to accelerate PSC research and drug development. Its many initiatives include creation of a PSC Patient Registry, an international database to create a synthetic arm for later stage clinical trials, and regulatory-grade, validated Patient-Reported Outcome Measures for major PSC symptoms. Safer serves on a number of healthcare-related boards and steering committees. She is a frequent presenter at medical conferences and has co-authored numerous posters and peer-reviewed scientific studies. Safer received a BA with honors from the University of Michigan and an MA degree from Johns Hopkins University. About Massimo Pinzani, MD, PhD, FRCP, FAASLD Professor Massimo Pinzani is a clinical and translational hepatologist and Emeritus Professor of Medicine at University College London (UCL). Until 2023 he was Sheila Sherlock Chair of Hepatology and Director of the UCL Institute for Liver and Digestive Health. Prof. Pinzani is a pioneer in researching cellular and molecular mechanisms of liver fibrosis and diagnostic and therapeutic approaches to managing liver fibrotic diseases. He has authored more than 300 peer-reviewed publications and has served as a board member of major hepatology and gastroenterology organizations, including the European Association for the Study of the Liver (EASL), and as an associate editor of major journals in the field. Prof. Pinzani was recently appointed Scientific Director of UPMC-ISMETT, a renowned center for transplantation and advanced specialized therapies in Palermo, Italy. About CM-101 Chemomab is assessing CM-101 as a potential treatment for PSC in the Phase 2 SPRING trial. CM-101 is a first-in-class monoclonal antibody that neutralizes CCL24, a soluble protein that helps drive the inflammatory and fibrotic pathways central to PSC and other fibro-inflammatory diseases. In clinical and preclinical studies, CM-101 appears safe, with the potential to treat multiple fibro-inflammatory disorders. Data from a Phase 2a liver fibrosis trial in nonalcoholic steatohepatitis (NASH) patients showed consistent, positive improvements in key inflammatory and fibrogenesis-related biomarkers, including several that may serve as a potential bridge to activity in PSC. Patient enrollment in the Phase 2 SPRING trial has been completed and a readout of topline data is expected midyear 2024. CM-101 has Orphan Drug status in the U.S. and E.U. and was awarded FDA Fast Track designation. A recording of the PSC KOL webinar will be available following the live session on Chemomab’s website at Chemomab Investor Relations - Presentations. About Chemomab Therapeutics Ltd. Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal role of CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody that neutralizes CCL24 activity. In clinical and preclinical studies, CM-101 appears safe, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported positive results from three clinical trials of CM-101 in patients, including a Phase 2a liver fibrosis trial in NASH patients and an investigator-initiated study in patients with severe lung injury. A Phase 2 trial in primary sclerosing cholangitis has completed patient enrollment, with topline data expected midyear 2024. Chemomab’s CM-101 program for the treatment of systemic sclerosis is Phase 2-ready. For more information about Chemomab, visit chemomab.com. Contact: Media and Investors: Barbara Lindheim Consulting Vice President, Investor & Public Relations, Strategic Communications Phone: +1 917-355-9234 barbara.lindheim@chemomab.com IR@chemomab.com